CriticalAntidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B)×Serotonin antagonist and reuptake inhibitor (SARI) antidepressant
Updated · Methodology
Mechanism
Trazodone inhibits serotonin reuptake at the presynaptic level and blocks 5-HT2A serotonin receptors at the postsynaptic level (trazodone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label classes it as a selective serotonin reuptake inhibitor (trazodone label, US Food and Drug Administration, FDA). Phenelzine is a potent non-selective inhibitor of monoamine oxidase (MAO), the enzyme that breaks down serotonin and other monoamines (phenelzine FDA label). MAO inhibitors impair serotonin metabolism and, together with serotonergic drugs such as trazodone, raise the risk of serotonin syndrome (trazodone FDA label).
Symptoms
Serotonin syndrome can be life-threatening (trazodone label, US Food and Drug Administration, FDA). It presents with mental status changes (agitation, hallucinations, delirium, coma), autonomic instability (fast heart rate, labile blood pressure, dizziness, sweating, flushing, high temperature), neuromuscular signs (tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, nausea, vomiting or diarrhoea (trazodone FDA label). Serious reactions with hyperthermia, rigidity, myoclonic movements and death have been reported when serotonergic drugs were combined with a monoamine oxidase (MAO) inhibitor (phenelzine FDA label). The Spanish trazodone summary of product characteristics (SmPC) describes serotonin syndrome and neuroleptic malignant syndrome with MAO inhibitors and other serotonergic drugs (trazodone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The US labels contraindicate the combination: trazodone is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping them, and phenelzine is contraindicated with serotonergic drugs (trazodone and phenelzine labels, US Food and Drug Administration, FDA). Phenelzine is not authorised in Spain and has no Spanish summary of product characteristics (SmPC). The Spanish trazodone SmPC is less strict: it does not recommend combining trazodone with MAOIs or starting it during the first 2 weeks after stopping them, although it notes that some doctors prescribe them together (trazodone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Start trazodone no earlier than 14 days after stopping phenelzine (trazodone and phenelzine FDA labels; trazodone SmPC, AEMPS). When switching from trazodone to phenelzine, the US trazodone label requires a gap of at least 14 days (trazodone FDA label). The phenelzine label says to wait until the serotonergic drug and its active metabolites have cleared (phenelzine FDA label). The Spanish trazodone SmPC does not recommend giving an MAOI one week after stopping trazodone (trazodone SmPC, AEMPS). If signs of serotonin syndrome appear, stop trazodone and other serotonergic drugs at once and start supportive symptomatic treatment (trazodone FDA label; trazodone SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Nardil (phenelzine sulfate tablets, USP) – prescribing information (2025)– FDA label, Parke-Davis Div of Pfizer, DailyMed setid 513a41d0-37d4-4355-8a6d-a2c643bce6fa, version 11, 06/2025, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- FDA: RALDESY (trazodone hydrochloride) prescribing information (2026)– FDA, DailyMed setid 34708cc1-b0b2-4fd0-b9f3-7f008b457fc9 (Validus), revisión 09/2026 (versión 6), secciones 5.2, 5.3, 5.9 y 7
- AEMPS: Ficha técnica: Trazodona, Deprax 100 mg (nº registro 78762), sección 4.5 (2023)– AEMPS, CIMA, nº registro 78762 (Deprax 100 mg comprimidos recubiertos con película, Angelini Pharma España), revisión 11/2023, secciones 4.4, 4.5 y 5.1